Emergent BioSolutions (EBS) Accumulated Expenses (2010 - 2026)

Emergent BioSolutions has reported Accumulated Expenses for 17 years, with the latest figure at $26.2 million in Q2 2026.

• On a quarterly basis, Accumulated Expenses fell 16.83% year-over-year to $26.2 million in Q2 2026; TTM through Jun 2026 was $26.2 million, a 16.83% decrease from a year earlier, with the FY2025 full-year figure at $41.8 million, down 25.49% from the prior year.
• Accumulated Expenses was $26.2 million for Q2 2026 at Emergent BioSolutions, up from $22.0 million in the prior quarter.
• The five-year high for Accumulated Expenses was $87.3 million in Q4 2022, with the low at $22.0 million in Q1 2026.
• Average Accumulated Expenses over 5 years is $55.2 million, with a median of $56.6 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2025: Accumulated Expenses climbed 17.72% in 2022, then plunged 52.77% in 2025.
• Over 5 years, Accumulated Expenses stood at $87.3 million in 2022, then fell by 15.12% to $74.1 million in 2023, then slipped by 24.29% to $56.1 million in 2024, then slipped by 25.49% to $41.8 million in 2025, then slumped by 37.32% to $26.2 million in 2026.
• The last three Accumulated Expenses figures came in at $26.2 million (Q2 2026), $22.0 million (Q1 2026), and $41.8 million (Q4 2025), per Business Quant data.